Detailed rationale

Crisil Ratings has reaffirmed its ‘Crisil AA-/Stable/Crisil A1+’ ratings on the bank facilities of Privi Speciality Chemicals Limited (PSCL, part of Privi group).

 

The ratings continue to reflect the strong business and financial risk profile of the Privi group. The Privi group reported revenues of Rs 1842 crore for 9 months ended Dec 2025 against Rs. 1488 crores for the same period of last year. The group is expected to achieve revenues of more than Rs. 2500 crores for fiscal 2026, driven by increase in capacity, healthy orders from customers and product additions and strong research and development (R&D). Operating margin improved to above 25% for the 9 months ending December 2025, from 21.57% for same period last year due to continuous R&D, debottlenecking of existing plant’s capacities leading to healthy input-output ratio, value addition products being manufactured using side streams and byproducts and several cost saving initiatives being implemented across all the manufacturing plants at Mahad and Jhagadia. The operating margins are expected to sustain above 22% over the medium-to-long term.

 

The financial risk profile of the company is marked by strong estimated networth of over Rs 1400 crore in fiscal 2026, Despite capex plans and operations remaining working capital intensive, debt levels remain at similar levels, resulting in gearing to remain less than 1 times over the medium term. Further with higher operating profit, interest coverage improved to around 7.555 times for Apr-Dec 2025 from 5 times for same period last year and is expected to remain at similar levels over the medium term. Liquidity is strong and expected to remain strong with healthy cash accruals against moderate repayment obligations, and average bank limit utilization of 79%. 

 

The ratings continue to reflect the group’s established market position in the bulk aroma chemicals industry, long-standing customer relationships, strong relationships with suppliers, and improving profitability and asset utilization levels. The ratings also consider the strong financial risk profile of the company. These strengths are partially offset by susceptibility to any changes in off-take by users, Exposure to sudden volatility in raw material prices, large working capital requirement and exposure to risks related to the ongoing capital expenditure (capex).

Analytical approach

For arriving at the ratings of PSCL, Crisil Ratings has consolidated the financials of PSCL and its wholly owned subsidiaries and joint ventures – Privi Biotechnologies Pvt Ltd, Privi Speciality Chemical USA Corp and Prigiv Specialties Pvt Ltd (Prigiv), which are strategically important to, and have a significant degree of operational integration with, PSCL. All the companies are collectively called the Privi group.

 

Loans from Givaudan India Pvt Ltd and Givaudan SA of Rs 232 crore as on September 30, 2025, are treated as debt.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key rating drivers - Strengths

Established market position, longstanding customer relationships, and diversified product basket: Benefits from the promoters' three and half decade-long experience in the industry, established relationships with suppliers and customers, and a portfolio of 78+ products (across different chemical categories - pinene, citral, phenol, sandalwood and musk & specialty) should continue to support the business. Pinene-based products—dihydromyrcenol, amber fleur, pine oil, terpeniol —account for sizeable revenue. With strong new products under development such as furfural, maltol, ethyl maltol and cyclopentanone, 10+ high end specialty products and 40+ products under Prigiv, the company is positioned to strengthen its foothold in the aroma and high-end specialty chemicals market.

 

Business is also bolstered by its key supplier status for all major global customers with which the company has a healthy relationship. It exports to all major markets and is the preferred supplier for the top flavour and fragrance (F&F) houses of the world such as Givaudan (Switzerland), Firmenich (Switzerland), Symrise (Germany), IFF (France) and leading fast moving consumer goods (FMCG) players such as P&G, RB and Henkel. PSCL’s established industry presence, diversified product basket and long and established relations with its reputed clientele bolsters its business risk profile and the same will also facilitate the steady ramp up in operations. In the first nine months of fiscal 2026, the company has already achieved revenue of more than Rs 1842 crore as compared to Rs 1488 crore for same period last year and is expected to post healthy revenue growth for fiscal 2026.

 

Strong R&D capabilities: Robust R&D capabilities enable the group to continuously innovate and develop new products as per the changing requirement of the end-user FMCG industry. The group has a R&D centre in Nerul and Mahad, both in Maharashtra. The R&D team has more than 139 people.

 

Strong relationships with suppliers, improving profitability and asset utilisation:

The company is one of the few players globally with the capability to manufacture key inputs alpha and beta pinene from basic raw materials, crude sulphate turpentine and/or gum turpentine oil. The backward integration for key inputs shields it from the fluctuations in alpha and beta pinene’s availability and prices. The arrangements with suppliers for raw material procurement also supports profitability. The tie-up of nearly 70% of its capacity with customers on yearly basis, insulates it from fluctuation in the prices of key products in spot market.

 

Strong financial risk profile: With steady accretion to reserve, the financial risk profile is strong, supported by estimated adjusted networth of more than Rs 1,400 crore as on March 31, 2026 (compared with Rs 1093 crore a year earlier). With moderate reliance on external debt, the capital structure is comfortable, as reflected in estimated gearing and total outside liabilities to adjusted networth (TOLANW) ratio of 0.7-0.8 time and 1.1–1.2 times, respectively, as on March 31, 2026 (1.01 and 1.53 times, respectively, a year earlier). Despite capex plans of Rs 900-1100 crore over the medium term, the capital structure is expected to improve further over the medium term, backed by healthy accretion to reserve. Debt protection metrics are healthy, as indicated by estimated interest coverage and net cash accrual to adjusted debt ratios of over 7.5 times and 0.35-0.45 times, respectively, in fiscal 2026 (5.19 times and 0.28 times, respectively, in fiscal 2025) and are expected to remain comfortable over the medium term. The financial risk profile will likely remain strong backed by healthy accretion to reserve, increased scale of operations and consequently moderate profitability.

Key rating drivers - Weaknesses

Exposure to any change in offtake by users, Exposure to sudden volatility in raw material prices: Demand for flavours and fragrances moves in line with the tastes and preferences of consumers. With changing tastes and preferences of consumers, FMCG companies are under pressure to constantly innovate and develop new affordable products. Accordingly, the Privi group must market its products in cost-effective ways to sustain its healthy operating margins. Operating performance is susceptible to changes in offtake by end-user industries and exposed to sudden and sharp fluctuation in foreign exchange (forex) rates and volatility in raw material prices.

 

Large working capital requirement: The working capital cycle is likely to remain large. Gross current assets (GCA) were 223 days as on March 31, 2025, driven by moderate receivables and high inventory. The receivables and inventory days as on September 30, 2025, were 63 and 170 (which is on reducing trend from last 3 fiscals), respectively, with higher quarter-end sales and stocking of key raw materials. The inventory levels are expected to be in a similar range in the medium term, as per business requirement given the lead time for imports and geopolitical situations. Furthermore, as the company deals with large global players, it has to extend an open credit of 75-85 days on average. GCAs are projected to be in a similar range over the medium term.

 

Exposure to risks related to the ongoing capex: PSCL is currently undertaking capacity expansion for multi-specialty products like maltol, ethyl maltol, and cyclopentanone and further plans the next phase of capex for specialty products. The estimated cost of capex is Rs 900-1000 crore, to be debt-funded to the extent of Rs 400-600 crore and likely to be completed in phases over the next 1-2 fiscals. The same will help the group to grow revenues by around Rs.1500-Rs.1600 crores over the medium term. The timely completion of the project with no major cost overruns, and subsequent increase in revenue will be a key monitorable.

Liquidity Strong

Expected annual cash accrual of Rs 424-550 crore should comfortably cover debt repayment of Rs 97-108 crore over the medium term. The fund-based working capital limits of Rs.535 crores was utilised 79%, on average, over the 12 months through December 2025. The group had unencumbered cash and equivalent of about Rs 45 crore as on September 30, 2025. The current ratio was moderate at 1.23 times as on March 31, 2025, and is estimated over 1.5 times as on March 31, 2026. Internal cash accrual and unutilised bank lines are sufficient to meet the incremental working capital requirement.

Outlook Stable

Crisil Ratings believes the Privi group will benefit from improving utilisation of capacities, healthy line-up of new products, addition of customers, and higher margin yielding products. A prudent funding mix and commitment towards maintenance of the capital structure and debt coverage will ensure sustenance of the financial risk profile over the medium term.

Rating sensitivity factors

Upward factors:

• Strengthening of the revenues and profitability leading to debt/earnings before interest, tax, depreciation and amortisation (Ebitda) lower than 1.6 times
• Sustenance of healthy financial risk profile and improvement in the working capital cycle

 

Downward factors:

• Gearing increasing to above 1.2 times, due to any further unanticipated capex or continued high inventory levels.
• Weaker profitability because of high cost of production, slower ramp up, or lower realisations, impacting cash accrual.

About the group

PSCL, incorporated in 1985, manufactures aroma chemicals, which are used as ingredients for manufacturing fragrances. The company has six manufacturing facilities at Mahad in Maharashtra and one in Jhagadia at Gujarat. PSCL has integrated operations with facilities to manufacture key raw materials. Mahesh Babani and D B Rao manage the operations.

 

The company has a wide product profile, which includes pinene-based, citral-based, phenol-based and other specialty products; customers comprise global leaders in flavour and fragrance, and FMCG industries. It is listed on both the National Stock Exchange and Bombay Stock Exchange.

 

Privi Biotechnologies Pvt Ltd: This is a 100% Subsidiary Company and is a R&D unit undertaking research and development activities exclusively for the parent company in producing natural aroma chemicals using the biotechnology route.

 

Privi Speciality Chemicals USA Corporation: This is a 100% subsidiary of PSCL, carrying out the marketing and distribution of PSCL's products in the US.

 

Prigiv Specialties Pvt Ltd: It is a JV Subsidiary Company with Givaudan SA for a strategic partnership in which PSCL has a 51% shareholding. The company has set up a new greenfield production facility in Mahad, and is planning to manufacture 40 products exclusively for Givaudan SA.

Any other information: Not Applicable

Annexure - List of Entities Consolidated

Names of entities consolidated	Extent of consolidation	Rationale for consolidation
Privi Speciality Chemicals Ltd	Full	Parent company
Privi Speciality Chemicals USA Corporation	Full	100% Wholly owned Subsidiary company
Privi Biotechnologies Pvt Ltd	Full	100% Wholly owned Subsidiary company
Prigiv Specialties Pvt Ltd*	Full (51%)	Joint Venture Subsidiary company

*51% owned by Privi Speciality Chemicals Ltd and 49% by Givaudan SA